GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IDEAYA Biosciences Inc (FRA:30J) » Definitions » Net Cash per Share

IDEAYA Biosciences (FRA:30J) Net Cash per Share : €6.75 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is IDEAYA Biosciences Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). IDEAYA Biosciences's Net Cash per Share for the quarter that ended in Dec. 2024 was €6.75.

The historical rank and industry rank for IDEAYA Biosciences's Net Cash per Share or its related term are showing as below:

FRA:30J' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.76   Med: 3.16   Max: 5.46
Current: 2.63

During the past 8 years, the highest Price-to-Net-Cash Ratio of IDEAYA Biosciences was 5.46. The lowest was 1.76. And the median was 3.16.

FRA:30J's Price-to-Net-Cash is ranked better than
63.15% of 844 companies
in the Biotechnology industry
Industry Median: 4.1 vs FRA:30J: 2.63

IDEAYA Biosciences Net Cash per Share Historical Data

The historical data trend for IDEAYA Biosciences's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEAYA Biosciences Net Cash per Share Chart

IDEAYA Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Cash per Share
Get a 7-Day Free Trial 5.11 3.83 6.39 7.01 6.75

IDEAYA Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.01 8.28 8.05 8.98 6.75

Competitive Comparison of IDEAYA Biosciences's Net Cash per Share

For the Biotechnology subindustry, IDEAYA Biosciences's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDEAYA Biosciences's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where IDEAYA Biosciences's Price-to-Net-Cash falls into.



IDEAYA Biosciences Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

IDEAYA Biosciences's Net Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as

Net Cash per Share (A: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(645.885-62.022-0)/86.504
=6.75

IDEAYA Biosciences's Net Cash per Share for the quarter that ended in Dec. 2024 is calculated as

Net Cash per Share (Q: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(645.885-62.022-0)/86.504
=6.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IDEAYA Biosciences  (FRA:30J) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


IDEAYA Biosciences Net Cash per Share Related Terms

Thank you for viewing the detailed overview of IDEAYA Biosciences's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


IDEAYA Biosciences Business Description

Traded in Other Exchanges
Address
5000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

IDEAYA Biosciences Headlines

No Headlines